Dark

Check out our API

DRNA
Dicerna Pharmaceuticals, Inc.
stock NASDAQ

Inactive

Dec 27, 2021

38.22USD+0.579%(+0.22)5,568,959

Pre-market

0.00USD-100.000%(-38.00)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Dec 25, 2021

09:38PM EST Dicerna Pharmaceuticals Inc. (DRNA) said that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Novo Nordisk's cash tender offer for Dicerna expired on December 24, 2021. RTTNews

08:45AM EST Dicerna Announces Expiration Of Hart-Scott-Rodino Act Waiting Period For Novo Nordisk Tender Offer To Acquire Dicerna RTTNews

Dec 14, 2021

05:55PM EST & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNA PR Newswire

Dec 9, 2021

09:50PM EST 10 Biggest Price Target Changes For Thursday Benzinga

09:50PM EST Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 Benzinga

09:44PM EST Chardan Capital Downgrades Dicerna Pharmaceuticals to Neutral, Raises Price Target to $38.25 Benzinga

08:41AM EST Direxion Launches mRNA ETF (MSGR) PR Newswire

Dec 2, 2021

12:58PM EST Dicerna Pharmaceuticals Option Alert: Jan 21 $35 Calls Sweep (4) near the Ask: 497 @ $3.5 vs 6158 OI; Ref=$38.07 Benzinga

Nov 24, 2021

04:08PM EST Dicerna Pharma Block Trade Of 500K Shares At $38/Share Benzinga

Nov 19, 2021

11:15PM EST & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNA PR Newswire

10:09AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 Benzinga

05:45AM EST RBC Capital Downgrades Dicerna Pharmaceuticals to Sector Perform, Raises Price Target to $38.25 Benzinga

Nov 18, 2021

02:36PM EST Mid-Afternoon Market Update: Dow Falls 75 Points; Dicerna Pharmaceuticals Shares Spike Higher Benzinga

12:35PM EST Mid-Day Market Update: Macy's Surges After Q3 Results; Amtech Systems Shares Plunge Benzinga

11:55AM EST HC Wainwright & Co. Downgrades Dicerna Pharmaceuticals to Neutral, Raises Price Target to $38.25 Benzinga

10:21AM EST Mid-Morning Market Update: Markets Down; Kohl's Earnings Top Expectations Benzinga

10:04AM EST Dicerna Shares Spike On Agreement To Be Acquired By Novo RTTNews

07:02AM EST Novo Nordisk To Acquire Dicerna For $38.25/Share In Cash Benzinga

Nov 12, 2021

08:06AM EST Dicerna Highlights Presentation Of Data From Phase 1 Trial Of Belcesiran At American Association For The Study Of Liver Diseases (AASLD) The Liver Meeting 2021 Benzinga

07:47AM EST The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares Benzinga

Nov 10, 2021

11:50AM EST Dicerna Pharmaceuticals's Return On Capital Employed Overview Benzinga

Nov 9, 2021

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:42AM EST Dicerna Pharmaceuticals: Q3 Earnings Insights Benzinga

11:41AM EST Dicerna Pharmaceuticals Expects $83M In Cash From Current Collaboration Agreements For FY21 Benzinga

11:41AM EST Dicerna Pharmaceuticals Q3 EPS $(0.22) Beats $(0.46) Estimate, Sales $62.95M Beat $43.78M Estimate Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

Nov 8, 2021

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

Nov 4, 2021

01:17PM EDT Dicerna Presents PHYOX2 And Primary Hyperoxaluria Healthcare Utilization Data At American Society Of Nephrology (ASN) Kidney Week 2021 Benzinga

08:19AM EDT The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 19, 2021

08:23AM EDT The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio Benzinga

07:35AM EDT Dicerna Announces Results For PHYOX4, Single-Dose Study Of Nedosiran In Primary Hyperoxaluria Type 3 (PH3); Study Met Primary Safety Endpoint, Study Did Not Meet Prespecified Secondary Efficacy Endpoint Benzinga

07:34AM EDT Dicerna Announces Results For PHYOX4, Single-Dose Study Of Nedosiran In Primary Hyperoxaluria Type 3 (PH3); Study Met Primary Safety Endpoint, Did Not Meet Prespecified Secondary Efficacy Endpoint Benzinga

Oct 15, 2021

04:04PM EDT Dicerna Announces Data To Be Presented At American Society Of Nephrology (ASN) Kidney Week 2021 Benzinga

Oct 14, 2021

04:55PM EDT Dicerna Highlights Will Give Poster Presentations At American Association For Study Of Liver Nov. 12-15, 2021 Benzinga

Sep 28, 2021

07:36AM EDT Dicerna Initiates Phase 1 Clinical Trial Of DCR-AUD, A Novel Investigational GalXC RNAi Therapeutic Candidate For Treatment Of Alcohol Use Disorder Benzinga

Aug 25, 2021

09:30AM EDT Dicerna Pharmaceuticals Sponsored Study Titled 'Phase 1 SAD Study of DCR-AUD in Healthy Volunteers' Posted To ClinicalTrials.Gov; Study Not Yet Recruiting Benzinga

Aug 21, 2021

12:30PM EDT Where Dicerna Pharmaceuticals Stands With Analysts Benzinga

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 11, 2021

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2021 Benzinga

09:41AM EDT Dicerna Pharmaceuticals Sponsored Study Titled 'Nedosiran in Pediatric Patients From Birth to 5 Years of Age With PH and Relatively Intact Renal Function (PHYOX8)' Posted To Clinical Trials Website; Study Not Yet Recruiting Benzinga

08:01AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

05:58AM EDT A Peek Into The Markets: US Stock Futures Mostly Lower; Inflation Data In Focus Benzinga

04:55AM EDT Goldman Sachs Downgrades Dicerna Pharmaceuticals to Neutral, Lowers Price Target to $25 Benzinga

Aug 10, 2021

01:06PM EDT What 10 Analyst Ratings Have To Say About Dicerna Pharmaceuticals Benzinga

08:58AM EDT Chardan Capital Maintains Buy on Dicerna Pharmaceuticals, Lowers Price Target to $28 Benzinga

06:37AM EDT HC Wainwright & Co. Maintains Buy on Dicerna Pharmaceuticals, Lowers Price Target to $32 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

10:24AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021 Benzinga

07:28AM EDT Dicerna Pharmaceuticals: Q2 Earnings Insights Benzinga

07:05AM EDT Dicerna Pharmaceuticals Q2 EPS $(0.53) Misses $0.41 Estimate, Sales $41.34M Miss $91.29M Estimate Benzinga

06:15AM EDT Citigroup Downgrades Dicerna Pharmaceuticals to Neutral, Announces $32 Price Target Benzinga

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 6, 2021

02:40PM EDT Mid-Afternoon Market Update: Dow Gains 140 Points; Spectrum Pharmaceuticals Shares Plummet Benzinga

12:24PM EDT Analyst Ratings For Dicerna Pharmaceuticals Benzinga

12:11PM EDT Mid-Day Market Update: Gold Drops 2.5%; Sphere 3D Shares Spike Higher Benzinga

10:24AM EDT RBC Capital Maintains Outperform on Dicerna Pharmaceuticals, Lowers Price Target to $30 Benzinga

10:18AM EDT Mid-Morning Market Update: Markets Mostly Higher; US Economy Adds 943,000 Jobs Benzinga

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 6, 2021 Benzinga

10:05AM EDT Shares of Dicerna Pharmaceuticals Inc. (DRNA) tanked nearly 35% despite the drug company's pivotal nedosiran study meeting primary endpoint. RTTNews

08:21AM EDT Goldman Sachs Maintains Buy on Dicerna Pharmaceuticals, Lowers Price Target to $36 Benzinga

08:08AM EDT SVB Leerink Maintains Outperform on Dicerna Pharmaceuticals, Lowers Price Target to $47 Benzinga

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

07:25AM EDT Cowen & Co. Downgrades Dicerna Pharmaceuticals to Market Perform Benzinga

07:25AM EDT Truist Securities Downgrades Dicerna Pharmaceuticals to Hold, Announces $32 Price Target Benzinga

Aug 5, 2021

04:35PM EDT UPDATE: Dicerna Says '"The heterogeneity of Uox response seen in participants with PH2...suggests more complexity in the PH2 disease biology than has been previously understood and will require further evaluation' Benzinga

04:35PM EDT UPDATE: Dicerna Says 'Uox reductions were significant in participants with PH1 while participants with PH2 (5 nedosiran and 1 placebo) showed inconsistent results in this trial.' Benzinga

04:34PM EDT UPDATE: Dicerna Reports PHYOX 2 Trial Met Key Secondary Endpoint Benzinga

04:26PM EDT Dicerna Shares To Resume Trade At 4:30 p.m. EDT Benzinga

04:23PM EDT Dicerna Reports Top-Line REsults From PHYOX 2 Trial Of Nedosiran For Treatment Of Primary Hyperoxaluria Met Primary Endpoint Benzinga

04:01PM EDT Dicerna Shares Halted News Pending Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 29, 2021

07:54AM EDT Dicerna Reports FDA Clearance Of Its Investigational New Drug Application For DCR-AUD For Treatment Of Alcohol Use Disorder Benzinga

Jul 21, 2021

09:17AM EDT Dicerna Posts Updated Data From Belcesiran Early-Stage Study For Genetic Liver Disease Benzinga

08:04AM EDT Dicerna Announces Interim Results From Phase 1 Trial Of Belcesiran For Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Benzinga

07:52AM EDT The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay Benzinga

Jul 7, 2021

07:41AM EDT The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend Benzinga

Jun 25, 2021

07:32AM EDT The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs Benzinga

Jun 23, 2021

06:18AM EDT HC Wainwright & Co. Maintains Buy on Dicerna Pharmaceuticals, Raises Price Target to $42 Benzinga

Jun 22, 2021

07:32AM EDT Dicerna Initiates Patient Dosing In ESTRELLA Phase 2 Clinical Trial Of Belcesiran For Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Benzinga

Jun 16, 2021

08:20AM EDT The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO Benzinga

07:34AM EDT Dicerna Announces Dosing Completion in Nedosiran PHYOX4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3 Benzinga

Jun 15, 2021

08:07AM EDT The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda Benzinga

Jun 9, 2021

09:14AM EDT The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US Benzinga

Jun 8, 2021

09:17AM EDT The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex Benzinga

May 27, 2021

07:41AM EDT Dicerna Announces FDA Acceptance Of Lilly's Investigational New Drug Application For LY3819469 Benzinga

May 24, 2021

12:29PM EDT Boehringer Ingelheim to Develop NASH Candidate Based On Dicerna's GalXC Platform Benzinga

07:31AM EDT Dicerna Announces Boehringer Ingelheim's Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement Benzinga

May 11, 2021

09:39AM EDT Lilly, MiNA Ink Broad RNA Deal Worth $1.25B Benzinga

May 6, 2021

05:05PM EDT Dicerna Pharmaceuticals Q1 EPS $(0.39) Misses $(0.37) Estimate, Sales $47.60M Beat $46.28M Estimate Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

Apr 30, 2021

07:31AM EDT The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs Benzinga

Apr 21, 2021

07:31AM EDT The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue Benzinga

Apr 16, 2021

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 16, 2021 Benzinga

06:13AM EDT Goldman Sachs Initiates Coverage On Dicerna Pharmaceuticals with Buy Rating, Announces Price Target of $48 Benzinga

Apr 8, 2021

01:00PM EDT SVB Leerink Maintains Outperform on Dicerna Pharmaceuticals, Lowers Price Target to $44 Benzinga

09:04AM EDT Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront Benzinga

08:34AM EDT Royalty Pharma plc (RPRX) has acquired Dicerna Pharmaceuticals Inc.'s (DRNA) royalty interest in OXLUMO or lumasiran for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. RTTNews

07:55AM EDT Royalty Pharma Acquires Dicerna's Royalty Interest In OXLUMO RTTNews

07:40AM EDT -- Dicerna to receive $180 million upfront and up to $60 million in potential additional milestone payments GlobeNewswire Inc

07:31AM EDT Dicerna Sells OXLUMO Royalty Interest to Royalty Pharma for Up to $240M; Dicerna To Receive $180M Upfront and Up to $60M in Potential Additional Milestone Payments Benzinga

Mar 30, 2021

01:59PM EDT Dicerna's RNAi Technology Shows Encouraging Action Against CNS Targets In Animal Studies Benzinga

10:51AM EDT Dicerna's GalXC-Plus RNAi Technology Delivers Target Knockdown Across CNS And To Specific CNS Cell Types In Preclinical Studies Benzinga

Mar 4, 2021

07:33AM EST Dicerna Announces Roche's Initiation of GalXC RNAi Candidate RG6346 in Phase 2 Combination Trial for Treatment of Chronic Hepatitis B Virus Infection Benzinga

Mar 3, 2021

07:46AM EST The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study Benzinga

Mar 2, 2021

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

07:41AM EST HC Wainwright & Co. Maintains Buy on Dicerna Pharmaceuticals, Raises Price Target to $40 Benzinga

05:08AM EST Chardan Capital Maintains Buy on Dicerna Pharmaceuticals, Raises Price Target to $34 Benzinga

Feb 26, 2021

08:17AM EST The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida Benzinga

Feb 25, 2021

05:09PM EST Recap: Dicerna Pharmaceuticals Q4 Earnings Benzinga

04:58PM EST Dicerna Pharmaceuticals Q4 EPS $(0.49) Misses $(0.03) Estimate, Sales $40.96M Miss $67.25M Estimate Benzinga

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 11, 2021

12:19PM EST Dicerna Starts Dosing With Nedosiran In Primary Hyperoxaluria Early-Stage Study Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Jan 12, 2021

08:16AM EST Dicerna Pharmaceuticals Says Selected Belcesiran For Clinical Advancement, With An Expected H1 2021 Phase 2 Trial Initiation, For Treatment Of AATLD Benzinga

Jan 5, 2021

04:05PM EST Dicerna to Participate in the H.C. Wainwright Virtual BioConnect Conference Business Wire

07:33AM EST Dicerna Announces Novo Nordisk's Nomination Of First Candidate For Development Under RNAi Discovery And Development Agreement And Additional Milestone Achievement Benzinga

Jan 4, 2021

07:35AM EST UPDATE: Dicerna Expects Trial Completion In First Half Of 2021, With Top-Line Data Available Mid-Year; Enrollment In PHYOX4 Trial For PH3 Expected To Begin In January 2021 Benzinga

07:34AM EST Dicerna Announces Enrollment Completion Of PHYOX2 Pivotal Trial Of Nedosiran For Treatment Of Primary Hyperoxaluria Benzinga

Dec 1, 2020

04:30PM EST Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Nov 25, 2020

03:52AM EST SVB Leerink Maintains Outperform on Dicerna Pharmaceuticals, Lowers Price Target to $45 Benzinga

Nov 16, 2020

07:36AM EST Dicerna Reports FDA Acceptance Of IND Filed By Eli Lilly For LY3561774 RTTNews

07:34AM EST Dicerna Announces Positive Updated Data From Phase 1 Trial Of RG6346 For Chronic HBV Infection RTTNews

07:31AM EST Dicerna Announces FDA Acceptance of Lilly's Investigational New Drug Application For First GalXC RNAi Candidate Under Companies' Global Research Collaboration And Licensing Agreement, Triggering $10M Payment To Dicerna Benzinga

07:31AM EST Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus (HBV) Infection at AASLD's The Liver Meeting(r) Digital Experience(tm) 2020 Business Wire

07:30AM EST Dicerna Announces FDA Acceptance of Lilly's Investigational New Drug (IND) Application for First GalXC(tm) RNAi Candidate Under Companies' Global Research Collaboration and Licensing Agreement Business Wire

Nov 11, 2020

04:05PM EST Dicerna to Participate in Upcoming Investor Conferences Business Wire

Nov 10, 2020

04:22PM EST Dicerna Presents New Nonclinical Research Highlighting Application Of Its RNAi Technology In Extrahepatic Tissues At TIDES Europe 2020 Benzinga

Nov 5, 2020

05:04PM EST Dicerna Pharmaceuticals Q3 EPS $(0.29) Misses $(0.20) Estimate, Sales $48.88M Miss $51.50M Estimate Benzinga

04:06PM EST Dicerna Announces Third Quarter 2020 Financial Results and Provides a Business Update Business Wire

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

04:30PM EST Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Nov 1, 2020

12:00PM EST Dicerna Announces Updated Phase 1 Data on RG6346 Investigational Treatment for Chronic Hepatitis B Virus to be Presented in Late-Breaking Session at AASLD's The Liver Meeting(r) Digital Experience(tm) 2020 Business Wire

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 29, 2020

04:06PM EDT Dicerna to Report Third Quarter 2020 Financial Results on November 5, 2020 Business Wire

Oct 22, 2020

10:13AM EDT Dicerna Presents Positive Interim Data From Study Of Nedosiran For Treatment Of Primary Hyperoxaluria RTTNews

10:09AM EDT Dicerna Pharma Reports New Interim Data From PHYOX 3 Long-Term, Open-Label Extension Study Of Nedosiran For Treatment Of Primary Hyperoxaluria: All Participants Achieved Normalization Or Near-Normalization Of Urinary Oxalate Benzinga

10:05AM EDT Dicerna Presents Positive New Interim Data From PHYOX(tm)3 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria (PH) Business Wire

Oct 16, 2020

12:03PM EDT Dicerna Pharmaceuticals Option Alert: Dec 18 $22.5 Calls Sweep (2) near the midpoint: 570 @ $1.525 vs 0 OI; Earnings 11/5 After Close [est] Ref=$20.41 Benzinga

Oct 13, 2020

04:05PM EDT Dicerna to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference Business Wire

07:00AM EDT VBL Therapeutics (Nasdaq: VBLT) today announced that it has appointed Marc Kozin as Vice Chairman of the Board. Mr. Kozin will transition to becoming Chairman during 2021, at which time Bennett Shapiro, M.D., the current Chairman of the Board, will step down as Chairman. Dr. Shapiro will remain on the Board of Directors. GlobeNewswire Inc

Oct 9, 2020

04:05PM EDT Dicerna to Present Nedosiran Data at American Society of Nephrology (ASN) Kidney Week 2020 Business Wire

Oct 1, 2020

04:30PM EDT Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Sep 28, 2020

04:05PM EDT Dicerna to Participate in the Chardan 4th Annual Genetic Medicines Conference Business Wire

Sep 16, 2020

07:33AM EDT Dicerna Appoints Ling Zeng As Chief Legal Officer And Secretary RTTNews

Sep 2, 2020

04:05PM EDT Dicerna to Participate in Upcoming September Investor Conferences Business Wire

Sep 1, 2020

04:30PM EDT Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Aug 7, 2020

07:30AM EDT SVB Leerink Maintains Outperform on Dicerna Pharmaceuticals, Raises Price Target to $46 Benzinga

06:59AM EDT HC Wainwright & Co. Maintains Buy on Dicerna Pharmaceuticals, Raises Price Target to $35 Benzinga

Aug 6, 2020

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

07:21AM EDT Dicerna Reports Clinical Data For Investigational Treatments RG6346 For Chronic Hep B Virus, Nedosiran For Primary Hyperoxaluria Benzinga

07:01AM EDT Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346 for Chronic Hepatitis B Virus and Nedosiran for Primary Hyperoxaluria, and Presents Preclinical Data Applying RNAi Technology in New Tissues Business Wire

07:01AM EDT Dicerna Announces Second Quarter 2020 Financial Results and Provides a Business Update Business Wire

Aug 5, 2020

04:06PM EDT Dicerna Announces Appointment of Shreeram Aradhye, M.D., as Executive Vice President and Chief Medical Officer Business Wire

Aug 3, 2020

04:30PM EDT Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Jul 24, 2020

07:30AM EDT Dicerna to Report Second Quarter 2020 Financial Results and Host Virtual Research and Development Event on Aug. 6, 2020 Business Wire

Share